1. Намазова-Баранова Л.С., Мурашкин Н.Н., Иванов РА. Биологическая терапия в эру COVID-19. Вопросы современной педиатрии 2020; 19(2): 116—122. DOI: 10.15690/vsp. v19i2.2104
2. Заплатников А.Л., Свинцицкая Л.С. COVID-19 и дети. РМЖ 2020; 28(6): 20—22.
3. Намазова-Баранова Л.С. Коронавирусная инфекция (COVID-19) у детей (состояние на апрель 2020). Педиатрическая фармакология 2020; 17(2): 85-94. DOI: 10.15690/pf.v17i2.2094
4. Методические рекомендации. Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19) у детей. Версия 2 (03.07.2020). https://static-0.minzdrav.gov.ru/sys-tem/attachments/attaches/000/050/914/original/03062020_%D0%B4%D0%B5%D1%82%D0%B8_COVID-19_v2.pdf
5. Balduzzi A., Brivio E., Rovelli A., Rizzari C., Gasperini S., Melzi M. et al. Lessons after the early management of the COVID-19 outbreak in a paediatric transplant and haema-to-oncology centre embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Bone Marrow Transplant 2020; 1-6. DOI: 10.1038/s41409-020-0895-4
6. Dong Y., Mo X., Hu Y., Qi X., Jiang F, Jiang Z., Tong S. Epidemiology of COVID-19 Among Children in China. Pediatrics 2020; 145(6): e20200702. DOI: 10.1542/peds.2020-0702
7. Lowensteyn Y.N., Phijfer E.W., Simons J.V.L., Schelte-ma N.M., Mazur N.I., Nair H. et al. Respiratory syncytial virus-related death in children with Down syndrome: the RSV GOLD study. Pediatr Infect Dis J 2020; 39(8): 665-670. DOI: 10.1097/INF.0000000000002666
8. Perez-Padilla R., Fernandez R., Garcia-Sancho C., Franco-Marina F., Aburto O., Lopez-Gatell H. et al. Pandemic (H1N1) 2009 virus and Down syndrome patients. Emerg Infect Dis 2010; 16(8): 1312-1314. DOI: 10.3201/eid1608.091931
9. Zhang C., Wu Z., Li J.W., Zhao H., Wang G.Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020; 29: 105954. DOI: 10.1016/j.ijantimicag.2020.105954
10. Chen Z, Xiong H., Li J.X., Li H., Tao F., Yang Y.T. et al. COVID-19 with post-chemotherapy agranulocytosis in childhood acute leukemia: a case report. Zhonghua Xue Ye Xue Za Zhi 2020; 41(4): 341-343. DOI: 10.3760/cma.j.issn.0253-2727.2020.0004
11. Feng K., Yun Y.X., Wang X.F., Yang G.D., Zheng Y.J., Lin C.M. et al. Analysis of CT features of 15 children with 2019 novel coronavirus infection. Zhong-hua Er Ke Za Zhi 2020; 58(4):275-278. DOI: 10.3760/cma.j.cn112140-20200210-00071
12. Park J.Y., Han M.S., Park K.U., Kim J.Y., Choi E.H. First Pediatric Case of Coronavirus Disease 2019 in Korea. J Korean Med Sci 2020; 35(11): e124. DOI: 10.3346/jkms.2020.35.e124
13. Alattar R., Ibrahim T.B.H., Shaar S.H., Abdalla S., Shukri K., Daghfal J.N et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol 2020; 10.1002/jmv.25964. DOI: 10.1002/jmv.25964
14. Capra R., De Rossi N., Mattioli F., Romanelli G., Scarpazza C., Sormani M. et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med 2020; 76: 31-35. DOI: 10.1016/j.ejim.2020.05.009
15. Toniati P., Piva S., Cattalini M., Garrafa E., Regola F., Castel-li F. et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev 2020; 19(7): 102568. DOI: 10.1016/j.autrev.2020.102568